THE CONTRIBUTION OF ONCOTARGET TOWARDS THYROID CANCER

Cancer is definitely not a new name to the world. It is however characterised or associated with negative matters such as death. Over the years, Cancer has been regarded as one of the highest causes of death in the world. Many people across the globe have been affected one way or the other by this disease hence increasing the alert of fatality of Cancer. A lot of deaths caused by cancer can be attributed by inefficient or lack of enough information concerning this fatal disease. Oncotarget is a scientific journal that majorly associates itself with Oncology (the study of diagnosis, prevention and treatment of cancer). By doing this, Oncotarget is able to help cancer patients start treatment before reaching a fatal stage. In addition to this, it is an open peer-reviewed Journal that is available to the public. Learn more about Oncotarget at Research Gate.

Most cases of Papillary Thyroid Carcinoma (the most popular type of thyroid cancer) are characterized with late diagnosis which means that the cancer is most probably incurable at this stage. This type of cancer is commonly treated using a drug known as Vemurafenib. A study done by a medical team at Harvard Medical School reviled evidence that a different drug, Palbociclib, that is used to treat advanced breast cancer, be able to treat Papillary Thyroid Carcinoma (PTC) that exhibits resistance towards Vemurafenib. These results were made public and published on the cover of Oncotarget. PTC’s genetic Hallmark is a particular mutation of the gene BRAF. Visit Oncotarget’s profile page at facebook.com

Patients who have the Mutation of BRAF gene are treated with drugs such as Vemurafenib that specifically target the mutated gene. In spite of these drugs’ specificity, most patients who are treated with Vemurafenib eventually form a resistance leaving cancer to develop and spread. According to the lead author of this study, Carmelo Nucera M.D., Ph.D, drug therapy using a combination of the two drugs (Vemurafenib and Palbociclib) will effectively treat PTC. Mr Carmelo currently works as an assistant professor at Havard Medical School. The same research team had previously established that thyroid cancer cells that are resistant to Vemurafenib have loss of P16 gene which explains the ability of cancer to develop despite treatment.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/